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Abstract 
Background: Cancers related to tobacco use and African-American ancestry are under-characterized by genomics. 
This gap in precision oncology research represents a major challenge in the health disparities in the United States. 
Methods: The Precision Oncology trial at the Wake Forest Baptist Comprehensive Cancer Center enrolled 431 
cancer patients from March 2015 to May 2016. The composition of these patients consists of a high representation 
of tobacco-related cancers (e.g., lung, colorectal, and bladder) and African-American ancestry (13.5%). Tumors 
were sequenced to identify mutations to gain insight into genetic alterations associated with smoking and/or 
African-American ancestry.  
Results: Tobacco-related cancers exhibit a high mutational load. These tumors are characterized by high-frequency 
mutations in TP53, DNA damage repair genes (BRCA2 and ATM), and chromatin remodeling genes (the lysine 
methyltransferases KMT2D or MLL2, and KMT2C or MLL3). These tobacco-related cancers also exhibit augmented 
tumor heterogeneities. Smoking related genetic mutations were validated by The Cancer Genome Atlas dataset that 
includes 2,821 cases with known smoking status. The Wake Forest and The Cancer Genome Atlas cohorts (431 and 
7,991 cases, respectively) revealed a significantly increased mutation rate in the TP53 gene in the African-American 
subgroup studied. Both cohorts also revealed 5 genes (e.g. CDK8) significantly amplified in the African-American 
population.  
Conclusions: These results provide strong evidence that tobacco is a major cause of genomic instability and 
heterogeneity in cancer. TP53 mutations and key oncogene amplifications emerge as key factors contributing to 
cancer outcome disparities among different racial/ethnic groups.  
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Introduction 
Advances in genomics and informatics have 
validated the importance of individuality in cancer 
diagnosis and treatment. Evidence illustrates that 
cancer is a disease of genetic and epigenetic causality, 
profoundly affected by environment and lifestyle [1]. 
An increasing number of genetic alterations have been 
characterized that drive the pathogenesis of cancer 
and convey therapeutic actionability [2]. These driver 
mutations often are not restricted to a specific cancer 
type, histology or patient demographic. This 
unprecedented molecular understanding of 
individual cancers has ushered in a new era of health 
care coined precision medicine [3].  
Precision medicine has begun a reprogramming 
of clinical oncology practice [4, 5]. Specialization in 
organ-oriented disease is being supplemented with 
molecular target assessment and targeted treatment 
across cancer types [6-9]. New clinical trial models 
(e.g., BASKET trial, NCI-MATCH) emphasize 
treatment decisions based on druggability of gene 
mutations rather than tumor histology [10, 11]. 
Precision medicine consortia have formed to test this 
new mode of cancer management [12]. The Precision 
Medicine Exchange Consortium (PMEC) is one such 
consortium, consisting of eight major cancer centers in 
the US, including the Wake Forest Baptist 
Comprehensive Cancer Center (WFBCCC).  
To investigate the relationship between precision 
medicine-derived cancer genomic correlates and 
patient demographics at WFBCCC, 431 cancer 
patients were enrolled into the Wake Forest Precision 
Oncology Initiative trial. This patient cohort reflects 
the patient population in the WFBCCC catchment 
area with a high representation of tobacco-related 
cancers (e.g., lung, colorectal, and bladder) and 
African American (AA) ancestry (13.5%). In the 
WFBCCC catchment area, (22% of adults are current 
tobacco users versus 19% nationally). Cigarette smoke 
is a known carcinogen, causing defined mutational 
signatures [13, 14]. However, smoking-related genetic 
changes in cancer are not well-characterized. Even 
more unclear is whether the mutational events differ 
between AA and Caucasian cancer patients, despite 
AA cancer patients having a poorer prognosis, 
including cancer-related and higher overall mortality 
rates [15]. 
Here, we report the characterization of the 
mutational landscapes of our unique cohort of cancer 
patients with findings validated in The Cancer 
Genome Atlas (TCGA) dataset. We also provide 
examples of mutation directed treatment in these 
patients to demonstrate the clinical impact of 
precision oncology initiatives.  
Material and Methods 
Patient Cohort 
Four hundred thirty-one cancer patients from 
the catchment area of the WFBCCC participated in the 
IRB-approved Wake Forest Precision Oncology 
Initiative (POI) from March 1, 2015 to May 30, 2016. 
African American status is based on self-reported 
ancestry. Each patient was consented for research 
analysis of sequencing results. Tumor specimens were 
evaluated by two board-certified pathologists to 
confirm diagnosis and classification. Tumor biopsies 
and surgical specimens were formalin-fixed and 
paraffin-embedded immediately following 
acquisition, according to standard clinical protocol. 
Tumor blocks of sufficient cellularity (>20%) and 
limited necrosis were selected and submitted to 
Foundation Medicine for FoundationOne® testing. 
The clinical management process is shown in Figure 
S1 and supplementary methods. ClinicalTrials.gov 
Identifier: NCT02566421 
Genomic Profiling 
Tumor tissue was subjected to Next Generation 
Sequencing (NGS) to identify mutations, 
rearrangements and copy number alterations 
spanning 415 cancer-related genes that make up the 
FoundationOne ® (F1) test (Foundation Medicine, 
Cambridge, MA) (Supplementary Methods) [16]. 
Statistical and Bioinformatic Analysis 
Nonsynonymous somatic mutation calls were 
quantified. Patients were assigned to low or high 
mutation load groups based on the cohort mean 
mutation number. Fisher’s exact test and 
Benjamini-Hochberg multiple testing adjustments 
were used to determine associations between 
mutation load and DNA damage genes and 
chromatin remodeling genes. Smoking status was 
defined by self-reported smoking history obtained 
from Cancer Registry and/or Epic Electronic Medical 
Record. Never smokers were defined as respondents 
who smoked less than 100 cigarettes in their lifetime. 
Based on evidence that smoking cessation reduces 
cancer risk by half at five years, active smokers at the 
time of clinical data collection and those who had quit 
smoking within the previous five years were 
considered current/recent smokers [17, 18]. Those 
having quit more than five years prior to data 
collection were defined as former smokers. Only 
white (Caucasian) and black (AA patients) were 
included in disparities analyses, as these are the two 
main ethnic groups of the WFBCCC catchment area. 
Other racial/ethnic populations were underrepre-
sented in the sample (less than 5%). Analyses for 
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discovery of smoking-related mutations focused on 
genes with functional roles in DNA Damage Repair 
and Chromatin Remodeling. Each set of analyses used 
the Cochran-Mantel- Haenszel test to uncover 
associations between smoking status (defined as an 
ordinal variable – Never, Former, Recent) and gene 
mutation. Fisher’s exact test was used to assess 
significance (p < 0.05) of gene mutation frequencies 
that differed with respect to low and high mutation 
load and racial status (Caucasians versus AA). The 
Hochberg (1988) approach was used to adjust for 
multiple testing [19]. MutSig algorithm, MutSigCV, 
was used to evaluate the significance of mutated 
genes. All analyses were performed with R statistical 
computing software version 3.3.0 [20]. Mutagenic 
processes and tumor clonality were analyzed with R 
packages somaticSignatures and SciClone, 
respectively (Supplementary Methods) [21]. 
Results 
Mutational Analysis 
We analyzed 431 cancer patients from the 
catchment area of the WFBCCC that participated in 
the IRB-approved Wake Forest Precision Oncology 
Initiative (POI). Patient demographics are 
summarized in Table 1, Table S1 and Figure 1. In our 
patients, the most frequently mutated genes were 
tumor suppressor genes TP53, APC, FAT1, RB1, 
BRCA2, and NF1; Wnt signaling pathway genes 
LRP1B and APC; oncogenes KRAS, PIK3A, DNA 
damage repair (DDR) genes (ATM, BRCA2); 
chromosomal integrity genes (TERT), and chromatin 
remodeling (CR) genes (KMT2D or MLL2, KMT2C or 
MLL3, ARID1A, ARID1B, EP300) (Figure 2A).  
Some of the observed gene mutations were 
expected. For example, TP53 showed a uniformly 
high frequency of mutation across all cancer types 
while APC was predominantly mutated in colorectal 
cancer. KRAS was mutated at high frequency in 
pancreatic, colorectal, and lung cancer. LRP1B was 
frequently mutated only in lung cancer (43 of 90, 
47.8%). Another gene highly mutated in lung cancer 
was SPTA1 (33 of 90, 37%) that has unknown 
oncogenic functions. Analysis of The Cancer Genome 
Atlas (TCGA) lung cancer cohort (adenocarcinomas 
and squamous) validated the frequent mutation of 
SPTA1 gene (Figure S2). EPHA3 and EPHA5 were also 
frequently mutated in both our and TCGA cohorts 
(Figure S2). TERT, which codes for telomerase and is 
involved in the longevity of tumor cells, was found to 
be frequently mutated at a promoter hot spot (-124C > 
T) in brain tumors (16 of 31, 53%), bladder cancers (9 
of 16, 56%), and head/neck cancers (6 of 26, 23%), 
consistent with recent reports [22, 23]. In contrast, the 
TERT promoter is rarely mutated in colorectal, lung or 
pancreatic cancer, or soft tissue sarcoma (Figure 2B).  
 
Table 1. Demographics of patients (N = 431) in the Precision 
Oncology Initiative 
Characteristic No. (%) 
SMOKING HISTORY  
Current 127 (29.5) 
Former 145 (33.6) 
Never 159 (36.9) 
RACE  
White or Caucasian 356 (82.6) 
Black or African American 58 (13.5) 
American Indian or Alaska Native 2 (0.5) 
Asian 5 (1.2) 
Native Hawaiian or Pacific Islander 1 (0.2) 
Other 9 (2.1) 
ETHNICITY  
Hispanic or Latino 8 (1.9) 
Not Hispanic or Latino 423 (98.1) 
CANCER STATUS  
Metastasis 185 (42.9) 
Primary 220 (51.0) 
Unknown 26 (6.0) 
DISEASE STAGE  
Stage 0 2 (0.5) 
Stage 1 31 (7.2) 
Stage 2 36 (8.4) 
Stage 3 85 (19.7) 
Stage 4 231 (53.6) 
Undetermined/Unknown 46 (10.7) 
TUMOR TYPE  
Lung 90 (20.9) 
Colorectal 56 (13.0) 
Other 43 (10.0) 
Cup 41 (9.5) 
Brain 31 (7.2) 
Sarcoma 30 (7.0) 
Head/Neck 26 (6.0) 
Other GI 21 (4.9) 
Breast 18 (4.2) 
Bladder 16 (3.7) 
Pancreas 16 (3.7) 
Ovary/Uterus 14 (3.2) 
Appendix 10 (2.3) 
Kidney 10 (2.3) 
Prostate 9 (2.1) 
 
A striking observation was the remarkably high 
mutation rates of DDR and CR genes in our cohort 
and their association with high-mutational load 
(Figure 3A, B, C), underscoring the highly unstable 
genome associated with smoking-related cancers that 
dominate our cohort.  
 Large numbers of gene mutations 
(hypermutation phenotype) and copy number 
alterations (chromosomal instability or CIN) 
represent two different types of genomic instability 
[24]. We observed that the CIN phenotype exhibited 
variable patterns in different cancer types, with 
extensive overall changes in lung and colorectal 
cancers (Figure S3A). Despite high mutation rates, 
two smoking-related cancer types, bladder and 
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head/neck cancers, did not show extensive copy 
number alterations (Figure 3C, Figure S3A). Among 
the most extensively amplified genes were oncogenes, 
including ERRB2, MYC, MET, CDK6, and EGFR (e 
Figure 3B). Two cases exhibited amplification of 
immunosuppressing genes PD-L1 (CD274) and PD-L2 
(PDCD1LG2), suggesting a role for anti-PD-1 or 
anti-PD-L1 therapy. Genes frequently deleted in our 
advanced cancer cohort are CDKN2A/B and PTEN 
(Figure S3B). 
 
 
Figure 1. Patient Demographics. (A) Patient smoking status within the context of type of cancer. (B) Patient race as described within cancer type. (C). Gender 
of patients within each cancer type. 
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Figure 2. Global Landscape of Somatic Mutations. (A) Global somatic mutational landscape of all patients for the top 30 genes having the largest fraction of 
mutations. Top and left bar charts show the number of mutations and percent of mutated samples, respectively. The lower part of panel A summarizes clinical 
information from each patient. (B) Somatic mutational landscape for major cancer groups for the same 30 genes seen in (A). Cancer group-wise mutational patterns 
show large similarities (TP53) but also striking differences (KRAS, APC, TERT) between cancer groups. 
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Figure 3. Associations between DDR/CR Gene Mutation Frequency, Tumor Mutational Load and Smoking Status. DDR and CR genes are mutated 
at higher frequency (A) and in tumors with higher mutation load (B). High and low mutational load (ML) designations are based on above-mean (orange) and 
below-mean (light green) mutation count, respectively. Nonsynonymous protein-altering mutations (SNVs, in/dels, rearrangements) and copy number deletions were 
included. **** (p < 0.0001); *** (p < 0.001); ** (p < 0.01); * (p < 0.05), Fisher’s exact test and Benjamini-Hochberg adjusting. (C) Mutational load across cancer groups 
as a function of smoking status. Boxes mark the interquartile range (25th-75th percentile) of the distribution while the whiskers demarcate the 5th and 95th percentiles. 
The white line marks the median of the distribution. 
 
Gene Mutations Associated with Smoking 
 In our cohort, proportions of smokers were 
similar in AAs and Caucasian-Americans (38 of 58, 
216 of 356, respectively; Fisher exact test p-value, 
0.56). Current/recent smokers exhibited a 
significantly higher mutational load (mean = 20.5, 
median = 14.0) than former smokers (mean = 13.0, 
median = 11.5; p = 0.017, 2-sided t-test) and never 
smokers (mean = 12.3, median = 11.0; p = 0.029, 
2-sided t-test). Analysis of total mutations per cancer 
showed a heterogeneous pattern (Figure S4) with 
lung, bladder, and colorectal cancer exhibiting high 
tumor mutational load. Appendiceal, brain, and 
prostate cancers exhibited the lowest mutational load.  
 Analysis of the mutational signatures 
characterized by nucleotide changes in the context of 
neighboring nucleotides identified three major 
signatures (Figure 4A). Current smokers, former 
smokers and never smokers exhibited distinct 
mutational signatures (Figure 4B). Many DDR and CR 
genes exhibited associations with smoking status 
(Figure 4C), with a greater frequency of mutation in 
current/recent or former smokers as compared to 
never smokers. After adjusting for multiple testing, 
mutations in two DDR genes – CDK12 and BRCA2 
met the criteria for statistical significance (p = 0.0069 
and 0.016, respectively). Similarly, the CR gene 
KMT2D met the criteria for statistical significance (p = 
0.0087), while two others (KDM6A and SMARCA4) 
were nominally significant (p = 0.026 and 0.032, 
respectively) (Figure 4C, Table S2). 
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Figure 4. Association of Gene Alterations and Smoking. (A) Three somatic mutational signatures present in the cohort. X-axis consists of adjacent nucleotides to the 
mutated base indicated on top of each column. Y-axis describes strength of contribution for a given triplet formed of altered base and adjacent nucleotides. (B) Contribution of 
each signature to smoking categories. (C) Significant smoking related alterations in DNA damage repair (DDR) and chromatin remodeling (CR) genes defined by the 
Cochran-Mantel-Haenzel test. (D) Validation for the smoking associated mutations in TCGA data. The validation dataset consists of 675 current smokers, 1351 former smokers 
and 795 never smokers. (E) Significant association between high tumor clonality and smoking. * (p < 0.05), ** (p < 0.01) 
 
To begin validation in the TCGA cohort we 
found that among the solid tumors, mutation and 
smoking status data was available in 2,821 cases. As 
shown in Figure 4D, current and former smokers have 
similar mutation frequencies of these genes. This 
analysis showed that most smoking-related gene 
mutations found in our cohort (e.g., KMT2D, BRCA2) 
were validated in the TCGA cohort.  
Intratumoral clonal heterogeneity poses serious 
challenges to precision oncology treatment [25]. 
Tumors comprised of multiple clones with different 
mutational events may require multiple targeting 
strategies; in combination or in sequence. We 
quantified tumor clonal heterogeneity based on 
clustering of variant allele fractions (Figure S5A, B, 
see Methods). Mutation rates for 48% of patients were 
relatively low with no clonal diversity. For the others, 
19, 23, and 10% of cases exhibited 1, 2 or more than 2 
clones, respectively, based on clonality analysis 
(Figure S5C). Higher clonality was associated with 
smoking (Figure 4E).  
Gene Mutations Associated with Race 
 The overall mutational landscape of AA patients 
is similar to that of the whole WFBCCC cohort, the 
majority of which are Caucasian patients (Figure 5A 
and Figure 2A). However, our analysis revealed 
differential mutation rates in the key genes, TP53 and 
KMT2C (Figure 5B). In the TCGA cohort, there are 842 
AA and 7,149 Caucasian cases with mutation data and 
892 AA and 7,679 Caucasians with gene amplification 
data. TP53 (p = 0.027), and to a lesser extent, KMT2C 
(p = 0.093), were more frequently mutated in AA 
patients in the TCGA cohort (Figure 5C). Gene copy 
number analysis revealed marked differences in five 
oncogenes in our cohort (Figure 5D); all of them were 
found to be more significantly amplified in AA in the 
TCGA cohort (Figure 5E).  
Precision Oncology Case Reports 
The essence of precision oncology is to match 
mutational information with drugs that have shown 
therapeutic efficacy in targeting the mutated protein. 
Oncologists at WFBCCC have designed clinical 
treatment regimens based on genomics testing in our 
Precision Oncology Trial and patients have shown 
remarkable responses. Key examples are described in 
Supplementary Material. 
 Theranostics 2017, Vol. 7, Issue 11 
 
 
http://www.thno.org 
2921 
 
Figure 5. Association of Mutations with AA Population. (A) Mutational landscape in AA cancers, 30 most frequently mutated genes. (B) Mutation frequencies 
among Caucasian and AA for significant race-associated genes. (C) Validation of TP53 mutation in AA in TCGA data. (D) Most common copy number alterations in 
AA. Genes with significant difference after adjustment are marked with asterisk. (E) Genes with significant connection between race and alteration status validated 
TCGA data are marked with asterisk * (p < 0.05), ** (p < 0.01), *** (p <0.001).  
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Discussion  
Smokers and AAs are more prevalent among our 
disproportionately rural, Appalachian/Piedmont 
catchment area population. Thus, we are able to 
uniquely interrogate mutations associated with these 
two understudied populations. This undertaking has 
provided a number of insights. Among the most 
interesting discoveries are the revelations that DDR 
and CR genes are highly mutated in current/former 
smokers, and smoking is associated with augmented 
clonal evolution (clonality) and tumor 
heterogeneities. This is consistent with recent genomic 
characterization of smoking related cancers [26]. 
These results provide strong evidence that genomic 
instability is a fundamental hallmark of cancer and 
the events underlying the regulation of genome 
stability are centered on interactions with 
environmental factors and lifestyle. 
AA cancer patients have a more dismal 
prognosis, which represents a key health disparity 
challenge in the US. Our genomics analysis revealed a 
number of genes mutated at different frequencies in 
AA and Caucasian cancer patients. After further 
analysis of the larger independent TCGA cohort, 
mutations of the tumor suppressor gene TP53 still 
emerged as a more common event in AA cancer 
patients. Notably, in our cohort of lung cancer, 
mutation rates for a number of genes including TP53 
are higher than that observed in the TCGA cohort, 
consistent with the predominance of advanced and 
smoking-related cancers in our cohort. However, our 
analysis showed that the enriched mutation in TP53 in 
AA is not driven by lung cancer in the cohort because 
TP53 mutation rates are similar in AA and Caucasian 
Americans (p = 0.5). TP53 has long been recognized as 
a critical control gene for genome stability [27]. 
Numerous studies have shown that mutations of 
TP53 are associated with poor prognosis in cancer 
[28]. Therefore, genomic stability regulated by TP53 
may be a key factor that contributes to cancer outcome 
disparities among different racial groups. The 
limitation of this study is the size of cohort enrolled in 
precision oncology initiatives due to the enrollment 
criteria and cost associated with the clinical 
sequencing tests. Therefore, future data sharing effort 
will enable pooled analysis of all the major precision 
oncology programs in the country to determine 
whether genetic events such as increased TP53 
mutation rates are observed in all major cancer types 
and their relationship with smoking. Interestingly, 
during the review of our study, a recent paper 
focusing on lung cancer reported overall similar 
mutation frequencies between AA and Caucasian 
American, however they also observed more 
prevalent TP53 mutation in AA subgroup than 
Caucasian group [29].  
In addition to gaining insight into the knowledge 
of genetic/molecular mechanisms of cancer 
development/progression, a key benchmark for 
precision oncology initiatives is the translatability of 
genomics information to more accurately targeted 
and beneficial treatments in patients [5, 30-33]. Several 
successful examples at WFBCCC are reported here 
and described in supplemental document.  
There is no doubt that increasing numbers of 
cancer patients will benefit from the precision 
oncology design. There are, however, a number of 
important challenges and limitations [34].  
First, the current precision oncology initiatives 
focus more on advanced metastatic cancer patients. 
Many of these patients die within 3-4 months of the 
genomic testing, before treatment decisions can be 
rendered. Thus, genomic testing should extend to 
patients with newly diagnosed metastatic disease, 
with the hypothesis that a patient with longer 
expected survival will benefit more from precision 
treatment. Retesting of tumors from recurrent patients 
will identify treatment-associated mutations to revise 
therapeutic strategies. Secondly, drug availability is a 
major problem [35-37]. Many FDA approved but 
off-label drugs, are not covered by insurance. Getting 
access to these off-label drugs on a compassionate 
basis invariably requires the resources and extra time 
of physicians. There clearly is a need for a streamlined 
process of drug acquisition for precision oncology to 
reach its full potential. Thirdly, genomic testing 
reveals many gene mutations without information 
about whether these mutations are deleterious (driver 
mutations). Thus, there is a clear need for efficient 
high throughput laboratory assays to identify 
functional mutations [38]. Fourthly, intratumoral 
heterogeneity poses a significant obstacle for 
sustained treatment response to a single agent 
therapy [25, 39]. Our clonality analyses showed that 
different clones exist in a fraction of tumors with 
different potential driver mutations. Therefore, 
precision oncology requires an understanding of 
tumor clonality to inform the design of combination 
or sequential therapy with different drugs. Finally, 
from the patients’ perspective, these complexities are 
compounded by the psychosocial and ethical 
considerations inherent to the genomic profiling 
process [40, 41]. In this newly evolving paradigm, 
patients and providers need to navigate care from a 
patient-centered framework. In the decision making 
process, smoking status and ethnicity should clearly 
be considered because of the association with 
differential mutation rates.  
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